SKG-0402 Market Summary

Key Factors Driving SKG-0402 Growth

1. Unmet medical need in Fabry disease

Fabry disease is a rare inherited lysosomal storage disorder caused by deficient α-Gal A activity, leading to the accumulation of globotriaosylceramide (Gb3) and related lipids in organs including the kidneys and heart. Existing treatments do not fully prevent disease progression in every patient. A gene therapy that enables sustained enzyme production could potentially address the underlying cause rather than relying on repeated enzyme replacement.

2. Potential for one-time treatment

As an AAV-based gene therapy, SKG-0402 is intended to deliver a functional GLA gene so that cells can produce α-Gal A. If successful, this approach could reduce the need for lifelong enzyme replacement infusions, typically administered every two weeks. However, durable enzyme expression and the ability to reduce or discontinue existing treatment have not yet been demonstrated in human studies of SKG-0402.

3. Preclinical efficacy in Fabry disease models

Skyline Therapeutics presented preclinical findings for SKG-0402 at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in May 2023, under the presentation title Efficacy of SKG0402 Gene Therapy in Fabry Disease Mouse Models. These studies provide an initial scientific rationale for development, although publicly accessible company announcements do not provide enough quantitative data to establish the magnitude or durability of benefit in humans.

4. Proprietary AAV vector-engineering platform

Skyline's capDRIVE platform combines capsid discovery, transgene design and vector engineering. The company presented preclinical data from multiple gene-therapy programs at ASGCT 2023 to demonstrate the platform's potential. If this technology improves gene delivery, expression or safety, it could support SKG-0402 development, although platform-level findings do not establish the candidate's clinical efficacy.

5. Potential to address kidney and cardiac complications

Fabry disease can cause progressive kidney impairment, left ventricular hypertrophy, cardiomyopathy and cerebrovascular complications. Restoring α-Gal A activity could potentially reduce pathological lipid accumulation and help preserve organ function. These serious complications create a clinical need for disease-modifying therapies, but SKG-0402 must demonstrate meaningful organ-level benefits in further studies before this becomes a validated growth driver.

SKG-0402 Recent Developments

Skyline Therapeutics presented crucial preclinical data detailing the efficacy of the SKG0402 gene therapy program in Fabry disease mouse models at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting. The data demonstrated targeted transgene design and efficient vector engineering using Skyline’s proprietary AAV capsid discovery platform.

“SKG-0402 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SKG-0402 for potential indication like Fabry’s disease in the 7MM. A detailed picture of SKG-0402’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SKG-0402 for potential indications. The SKG-0402 market report provides insights about SKG-0402’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SKG-0402 performance, future market assessments inclusive of the SKG-0402 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SKG-0402 sales forecasts, along with factors driving its market.

SKG-0402 Drug Summary

SKG-0402 is an investigational gene therapy candidate developed by Skyline Therapeutics for the potential treatment of Fabry disease, a rare, inherited X-linked lysosomal storage disorder caused by mutations in the GLA gene, which result in deficient alpha-galactosidase A (α-Gal A) enzyme activity and the accumulation of glycosphingolipids, including globotriaosylceramide (Gb3), in various organs and tissues. SKG-0402 is an adeno-associated virus (AAV)-based gene therapy designed to deliver genetic material that may enable cells to produce functional α-Gal A, thereby addressing the underlying enzyme deficiency and potentially reducing disease-associated substrate accumulation in the kidneys, heart and other affected organs. By aiming to restore enzyme activity through gene transfer, the therapy could potentially offer a longer-lasting treatment approach compared with conventional enzyme replacement therapy, which requires repeated intravenous infusions. The report provides SKG-0402’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SKG-0402 Market Report

The report provides insights into:

• A comprehensive product overview including the SKG-0402 MoA, description, dosage and administration, research and development activities in potential indication like Fabry’s disease.
• Elaborated details on SKG-0402 regulatory milestones and other development activities have been provided in SKG-0402 market report.
• The report also highlights SKG-0402‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The SKG-0402 market report also covers the patents information, generic entry and impact on cost cut.
• The SKG-0402 market report contains current and forecasted SKG-0402 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SKG-0402 market report also features the SWOT analysis with analyst views for SKG-0402 in potential indications.

Methodology

The SKG-0402 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SKG-0402 Analytical Perspective by DelveInsight

• In-depth SKG-0402 Market Assessment

This SKG-0402 sales market forecast report provides a detailed market assessment of SKG-0402 for potential indication like Fabry’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SKG-0402 sales data uptil 2034.

• SKG-0402 Clinical Assessment

The SKG-0402 market report provides the clinical trials information of SKG-0402 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SKG-0402 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SKG-0402 Market Potential & Revenue Forecast

• Projected market size for the SKG-0402 and its key indications
• Estimated SKG-0402 sales potential (SKG-0402 peak sales forecasts)
• SKG-0402 Pricing strategies and reimbursement landscape

SKG-0402 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SKG-0402 Market positioning compared to existing treatments
• SKG-0402 Strengths & weaknesses relative to competitors

SKG-0402 Regulatory & Commercial Milestones

• SKG-0402 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SKG-0402 Clinical Differentiation

• SKG-0402 Efficacy & safety advantages over existing drugs
• SKG-0402 Unique selling points

SKG-0402 Market Report Highlights

• In the coming years, the SKG-0402 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SKG-0402 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKG-0402’s dominance.
• Other emerging products for Fabry’s disease are expected to give tough market competition to SKG-0402 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKG-0402 in potential indications.
• Analyse SKG-0402 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SKG-0402 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SKG-0402 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SKG-0402? How strong is SKG-0402’s clinical and commercial performance?
• What is SKG-0402’s clinical trial status in each individual indications such as Fabry’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKG-0402 Manufacturers?
• What are the key designations that have been granted to SKG-0402 for potential indications? How are they going to impact SKG-0402’s penetration in various geographies?
• What is the current and forecasted SKG-0402 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SKG-0402 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SKG-0402 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is SKG-0402? What is the duration of therapy and what are the geographical variations in cost per patient?